Literature DB >> 1827433

Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study.

T D Brown1, P J Goodman, T R Fleming, L H Baker, J S Macdonald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1827433     DOI： 10.1007/bf00194550

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.

Authors:  C N Sternberg; G B Magill; E W Cheng; P Hollander
Journal:  Am J Clin Oncol       Date:  1988-04       Impact factor: 2.339

2.  One-sample multiple testing procedure for phase II clinical trials.

Authors:  T R Fleming
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

3.  Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent.

Authors:  J P McGovren; G L Neil; R H Denlinger; T L Hall; S L Crampton; J A Swenberg
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

4.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

5.  Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.

Authors:  F A Dorr; D D Von Hoff; J G Kuhn; R Schwartz; D L Kisner
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.